Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

Nissen, Steven E.; Tsunoda, Taro; Tuzcu, E. Murat; Schoenhagen, Paul; Cooper, Christopher J.; Yasin, Muhammad; Eaton, Gregory M.; Lauer, Michael A.; Sheldon, W. Scott; Grines, Cindy L.; Halpern, Stephen W.; Crowe, Tim; Blankenship, James C.; Kerensky, Richard A.

doi:10.1001/jama.290.17.2292

articleJAMANov 4, 2003HYBRID OA

Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes

SESteven E. Nissen TTTaro Tsunoda EME. Murat Tuzcu PSPaul SchoenhagenCJChristopher J. Cooper

Cleveland Clinic · Toho University · +7 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Objective

We assessed the effect of intravenous recombinant ApoA-I Milano/phospholipid complexes (ETC-216) on atheroma burden in patients with acute coronary syndromes (ACS).

Design

The study was a double-blind, randomized, placebo-controlled multicenter pilot trial comparing the effect of ETC-216 or placebo on coronary atheroma burden measured by intravascular ultrasound (IVUS).

Citation impact

1,704

total citations

FWCI: 70.35
Percentile: 100%
References: 26

Citations per year

Authors

14

SE
Steven E. NissenCorresponding
Cleveland Clinic
TT
Taro Tsunoda
Toho University, Children’s Village
EM
E. Murat Tuzcu
Cleveland Clinic, Children’s Village
PS
Paul Schoenhagen
Cleveland Clinic, Children’s Village
CJ
Christopher J. Cooper
Children’s Village, University of Toledo

Topics & keywords

Topics

Keywords

Medicine
Atheroma
Intravascular ultrasound
Placebo
Internal medicine
Cardiology
Confidence interval
Coronary atherosclerosis

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.